BriaCell Therapeutics Corp. (BCTX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$3.40

From 52W high−75.49%

Volume51869.00

Market cap$29.41M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$3.40

From 52W high

−75.49%

Volume

51869.00

Market cap

$29.41M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

P/E (TTM)

—

RSI (14)

36.5

MomentumView details →

1D Return

−0.59%

YTD Return

−51.65%

SummaryUpdated Apr 1, 2026

BriaCell Therapeutics Corp. (NASDAQ:BCTX) is a Canadian immuno-oncology biotechnology company founded in 2012 and headquartered in West Vancouver, Canada. The company went public on March 14, 2012, and focuses on developing innovative immunotherapies specifically designed to treat various forms of cancer. BriaCell operates as a clinical-stage biopharmaceutical company with no current commercial products, dedicating its resources to advancing novel cancer treatment approaches through its proprietary immunotherapy platform.

Ask drillr about BriaCell Therapeutics Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.2x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−154.06%

ROA (TTM)

−136.91%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+71.73%

FCF YoY

−7.69%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−45.55%

EBITDA YoY

−33.33%

MomentumView details →

1D Return

−0.59%

YTD Return

−51.65%

1Y Return

−71.68%

RSI (14)

36.5

vs 50D SMA

−9.34%

vs 200D SMA

−13.96%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

7.07x

Quick Ratio

7.07x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.99

EPS Surprise

—

Beats (12Q)

4/12

Next Q EPS Est

—

Avg Surprise (4Q)

−2696.66%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−37.06M

Op. CF (TTM)

−36.94M

Latest newsMore news →

BriaCell Therapeutics Corp. completed a best-efforts follow-on offering of 1,449,300 common shares at $3.25 per share for gross proceeds of $4.71 million, with ThinkEquity LLC as placement agent.139d ago

Similar companies

Evaxion Biotech A/SEVAX TransCode Therapeutics, Inc.RNAZ Galecto, Inc.GLTO Aligos Therapeutics, Inc.ALGS Barinthus Biotherapeutics plcBRNS Sangamo Therapeutics, Inc.SGMO Find similar companies →

Latest newsMore news →